Stepped-wedge trial design to evaluate Ebola treatments

The Lancet Infectious Diseases

Volumn 15, Issue 7, 2015, Pages 762-763

  Piszczek, Jolanta ^a   Partlow, Eric ^a  

^a Island Health ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA HEMORRHAGIC FEVER VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; EBOLA VACCINE;

CLINICAL TRIAL (TOPIC); EBOLA HEMORRHAGIC FEVER; HUMAN; LETTER; PRIORITY JOURNAL; STUDY DESIGN; EBOLAVIRUS; EPIDEMIC; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; ISOLATION AND PURIFICATION;

DISEASE OUTBREAKS; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 84937427595     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00078-X     Document Type: Letter

References (4)

1. Tully C, Lambe T, Gilbert S, et al. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. Lancet Infect Dis 2015, 15:356-359.
2. Sierra Leone to Introduce a Vaccine against Ebola (STRIVE) Centers for Disease Control and Prevention, (accessed June 4, 2015). http://www.cdc.gov/vhf/ebola/strive/qa.html.
3. Brown CA, Lilford RJ The stepped wedge trial design: a systematic review. BMC Med Res Methodol 2006, 6:54.
4. Dreischulte T, Grant A, Donnan P, Guthrie B Pros and cons of the stepped wedge design in cluster randomised trials of quality improvement interventions: two current examples. Trials 2013, 14(suppl 1):O87.